Neurology

The Biology: Antibodies and Hidden Cancers

At a Glance

In paraneoplastic polyneuropathy, antibodies that attack nerve proteins can signal an underlying cancer, often before routine scans find it. The antibody type helps doctors choose further imaging, repeat screening, and treatment.

To understand paraneoplastic polyneuropathy (PPN), it helps to view your immune system as a highly trained defense force that has made an error. In a healthy body, your immune system ignores your own cells. However, some tumors—most notably Small Cell Lung Cancer (SCLC)—contain proteins that are also found in your nerve cells ^[1].

When your immune system detects these “neural” proteins on a tumor, it recognizes them as foreign and mounts a response ^[1]. Because your healthy nerves share these same proteins, they become damaged in what is known as immune cross-reactivity ^[2].

The “Intracellular” Problem: Estimating the Mechanism

The location of the target protein matters significantly when doctors are estimating the mechanism of your disease and your responsiveness to treatment ^[3]. Most antibodies associated with PPN target proteins hidden inside the nerve cell (intracellular targets) rather than on its surface.

T-Cell Involvement: When a target is inside the cell, the antibody’s presence often indicates that the immune system is using T-cells to attack the tissue ^[2].
Reversibility: Because T-cell mediated attacks often lead to the death of the nerve cell, the damage can be difficult to reverse ^[4]. Treatment for these cases usually focuses on stabilizing the condition rather than fixing old damage ^[5].
Surface Targets: In contrast, some antibodies target proteins on the cell’s surface. While these syndromes can sometimes be interrupted by treatments more effectively, outcomes vary, and surface antibodies do not guarantee recovery ^[6]^[7].

The Key Antibodies and Their Cancer Connections

Doctors use specific antibodies to tell them which cancers to investigate. In many cases, these nerve symptoms appear before the cancer is detected on a standard scan ^[8].

Antibody Name	Common Cancer Association	Typical Nerve Symptoms
Anti-Hu (ANNA-1)	Strongly associated with Small Cell Lung Cancer ^[8].	Severe loss of balance (sensory ataxia) and “patchy” numbness ^[8].
CRMP5 (CV2)	Associated with Small Cell Lung Cancer and Thymoma ^[9].	Painful neuropathy; can also affect vision or coordination ^[10].
PCA-2	Strongly associated with Small Cell Lung Cancer ^[11].	Widespread nerve pain and weakness ^[11].
Amphiphysin	Associated with Breast Cancer and Small Cell Lung Cancer ^[12].	Stiff muscles or severe nerve pain; triggers search for lung or breast tumors ^[13].

The Search for the “Occult” Tumor

If you test positive for one of these antibodies but your initial chest X-ray or CT scan is clear, your doctors will likely not stop there. Because these antibodies suggest specific associations, doctors may order more sensitive imaging, such as a PET scan, which uses a radioactive tracer to find active cancer cells that other scans might miss ^[8].

Surveillance duration and intervals depend on your specific antibody risk, age, sex, cancer risk, and initial evaluation. For high-risk individuals, current guidelines often suggest an individualized plan that may extend cancer screening for several years ^[8]. Finding and treating the tumor as early as possible is an important step in protecting your nerves from further immune attack ^[14].

Why This Biology Matters for You

Knowing your specific antibody helps your care team evaluate how your disease might behave. While a diagnosis like “Anti-Hu” can be intimidating because of its strong link to SCLC and its T-cell involvement, it provides a clear roadmap for your doctors ^[8]. It tells them exactly which cancer to look for and helps them evaluate which immunotherapies might be necessary to quiet your immune system ^[15]^[16].

Common questions in this guide

What do antibody results mean in paraneoplastic polyneuropathy?

The antibody pattern can help doctors identify the type of immune response and decide which cancers to investigate. Anti-Hu and PCA-2 are strongly associated with small cell lung cancer, while CRMP5 and amphiphysin can be associated with small cell lung cancer, thymoma, or breast cancer.

Can nerve symptoms appear before the cancer is found?

Yes. Paraneoplastic nerve symptoms may start before a tumor is visible on a routine chest X-ray or CT scan. A negative first scan does not always end the evaluation, so your doctors may recommend more sensitive imaging and follow-up screening.

Why does it matter whether an antibody is inside or on the surface of nerve cells?

Antibodies aimed at proteins inside nerve cells often signal an immune attack involving T cells, which can destroy nerve cells and leave lasting damage. Antibodies aimed at the cell surface may be more responsive to treatment in some cases, but they do not guarantee recovery.

How are hidden cancers looked for after a positive antibody test?

Doctors may use a PET scan or other sensitive imaging when a chest X-ray or CT scan does not show a tumor. The timing and length of repeat screening depend on the antibody, your age, sex, cancer risk, and initial results; some people need monitoring for several years.

Can treatment restore nerve function in paraneoplastic polyneuropathy?

Recovery depends on the antibody, the immune mechanism, how much nerve-cell injury has occurred, and whether the underlying cancer is treated. Immunotherapy may help quiet ongoing immune activity and prevent additional damage, but established injury from an intracellular antibody may be difficult to reverse.

Which cancers are most often linked to paraneoplastic polyneuropathy?

Small cell lung cancer is the main cancer association discussed, especially with Anti-Hu and PCA-2 antibodies. CRMP5 may also be linked to thymoma, and amphiphysin may be associated with breast cancer or small cell lung cancer.

Get notified when new evidence is published on paraneoplastic polyneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (16)

1
Mechanisms of immune tolerance breakdown in paraneoplastic neurological syndromes.
Peter E, Dumez P, Honnorat J, Desestret V
Revue neurologique 2024; (180(9)):931-939 doi:10.1016/j.neurol.2024.08.002.
PMID: 39299842
2
Mechanisms of paraneoplastic neurological syndromes.
Kunchok A, Vogrig A, Graus F
Current opinion in neurology 2026; (39(3)):370-377 doi:10.1097/WCO.0000000000001488.
PMID: 41979003
3
Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy.
Zekeridou A, Lennon VA
Mayo Clinic proceedings 2019; (94(9)):1865-1878 doi:10.1016/j.mayocp.2019.02.003.
PMID: 31358366
4
Paraneoplastic Neurologic Disorders.
Zekeridou A
Continuum (Minneapolis, Minn.) 2024; (30(4)):1021-1051 doi:10.1212/CON.0000000000001449.
PMID: 39088287
5
Identifying a therapeutic window in acute and subacute inflammatory sensory neuronopathies.
Antoine JC, Robert-Varvat F, Maisonobe T, et al.
Journal of the neurological sciences 2016; (361()):187-91.
PMID: 26810539
6
Pathogenesis and immunopathology of paraneoplastic disorders.
Quinot V, Höftberger R
Handbook of clinical neurology 2024; (200()):33-54 doi:10.1016/B978-0-12-823912-4.00027-X.
PMID: 38494287
7
Paraneoplastic Disorders of the Nervous System.
Flanagan EP
Continuum (Minneapolis, Minn.) 2020; (26(6)):1602-1628 doi:10.1212/CON.0000000000000941.
PMID: 33273174
8
Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis.
Villagrán-García M, Farina A, Muñiz-Castrillo S, et al.
Brain communications 2023; (5(5)):fcad247 doi:10.1093/braincomms/fcad247.
PMID: 37794924
9
CRMP5 Antibodies-Diagnostic Challenges.
Totland C, Haugen M, Vedeler C
Frontiers in neurology 2021; (12()):729075 doi:10.3389/fneur.2021.729075.
PMID: 34630302
10
An overview on CV2/CRMP5 antibody-associated paraneoplastic neurological syndromes.
Wang S, Hou H, Tang Y, et al.
Neural regeneration research 2023; (18(11)):2357-2364 doi:10.4103/1673-5374.371400.
PMID: 37282453
11
Microtubule-associated protein 1B: Novel paraneoplastic biomarker.
Gadoth A, Kryzer TJ, Fryer J, et al.
Annals of neurology 2017; (81(2)):266-277 doi:10.1002/ana.24872.
PMID: 28074593
12
Paraneoplastic neuropathies and peripheral nerve hyperexcitability disorders.
Shelly S, Dubey D, Mills JR, Klein CJ
Handbook of clinical neurology 2024; (200()):239-273 doi:10.1016/B978-0-12-823912-4.00020-7.
PMID: 38494281
13
Antibodies to neural cell surface and synaptic proteins in paraneoplastic neurologic syndromes.
Budhram A, Sechi E
Handbook of clinical neurology 2024; (200()):347-364 doi:10.1016/B978-0-12-823912-4.00006-2.
PMID: 38494289
14
Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments.
Shah S, Vazquez Do Campo R, Kumar N, et al.
Neurology 2021; (96(4)):e632-e639 doi:10.1212/WNL.0000000000011218.
PMID: 33208548
15
Long lasting trigeminal neuropathy, limbic encephalitis and abdominal ganglionitis without primary cancer: An atypical case of Hu-antibody syndrome.
De Schamphelaere E, Sieben A, Heyndrickx S, et al.
Clinical neurology and neurosurgery 2020; (194()):105849 doi:10.1016/j.clineuro.2020.105849.
PMID: 32388246
16
Effectiveness of Intravenous Cyclophosphamide in a Patient With Anti-amphiphysin Autoimmunity Presenting With Bulbar Palsy and Cerebellar Ataxia: A Case Report.
Nomoto J, Takatsu H, Yoshida K, et al.
Cureus 2024; (16(7)):e65350 doi:10.7759/cureus.65350.
PMID: 39184604

This page is for informational purposes only and does not constitute medical advice. Your neurologist and oncology team should interpret antibody results and recommend the right cancer screening and treatment plan for you.